Risk factors
Theriva Biologics (TOVX) risk factors
Item 1A of every Theriva Biologics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors58 risks8 new1 dropped13 reworded
The company faces going concern doubts with an accumulated deficit of $358.7 million, needing capital while using $16.7 million in operating cash.
Filed Mar 12, 2026 - FY2024 10-K risk factors51 risks
Theriva Biologics faces going concern warnings with $11.6 million in cash against $16.9 million in annual operating losses. The company relies heavily on clinical development of its lead oncolytic virus candidate VCN-01 for pancreatic cancer. Operations are vulnerable to third-party manufacturing dependencies, strict FDA and European regulations, and required future capital raises.
Filed Mar 06, 2025